Pfizer Inc., plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture investment vehicle. According to the company, Pfizer Ventures seeks to invest twenty-five percent of its available capital ($150 million) in “promising early-stage neuroscience companies.” By